Auto-Cd34+ Cells
Peripheral Vascular Disease
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Peripheral Vascular Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atorvastatin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Telcagepant Merck Sharp & Dohme LLC | Phase 3 | BB |
Uniprost United Therapeutics | Phase 3 | B |
pf-00489791 Pfizer | Phase 2 | B |
Marcaine Jose Soberon, MD | Phase 2/3 | B |
Polycap St. John's Research Institute | N/A | D |
Rosuvastatin AstraZeneca | Unknown | D |
Tilmanocept Massachusetts General Hospital | Unknown | D |
Same molecule, other indications
Auto-Cd34+ Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →